International Journal of Hypertension / 2011 / Article / Tab 3

Research Article

Effects of Docosahexaenoic Acid Supplementation on Blood Pressure, Heart Rate, and Serum Lipids in Scottish Men with Hypertension and Hypercholesterolemia

Table 3

ω-3 and ω-6 fatty acids in plasma phospholipids at baseline and at 5 weeks and change from the baseline.

Fatty acidPlacebo ( )DHA ( )
Baseline5 WeeksChange (5-weeks-baseline)Baseline5 WeeksChange (5-weeks-baseline)

EPA (C20:5) (%)1.50 ± 1.131.53 ± 0.790.04 ± 1.091.24 ± 1.301.65 ± 1.200.41 ± 1.13
DHA (C22:6) (%)1.58 ± 0.641.47 ± 0.64−0.11 ± 0.781.04 ± 0.473.40 ± 0.90***2.36 ± 0.79†††
PUFAs ω-3 series (%)3.08 ± 1.543.00 ± 1.14−0.07 ± 1.412.28 ± 1.615.05 ± 1.86**2.77 ± 1.64†††
PUFAs ω-6 series (%)16.0 ± 5.819.3 ± 5.1**3.38 ± 4.4517.1 ± 7.018.3 ± 4.31.29 ± 5.64
ω-3/ω-6 Ratio0.24 ± 0.180.17 ± 0.09*−0.07 ± 0.140.15 ± 0.130.30 ± 0.18**0.15 ± 0.14†††

EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid, PUFAs: polyunsaturated fatty acids.
PUFAs ω-3 series: EPA + DHA; PUFAs ω-6 series: arachidonic acid + linoleic acid.
Placebo: Olive oil-containing bread rolls, DHA: DHA-containing bread rolls. Values are presented as mean ± SD.
* , ** , and *** compared with the baseline. ††† compared with the placebo group.